Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 3/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3864619 | 0.90 | LMNA (0.50) | LMNAMAPTTP53TSHRRAB9A | |
| SCHEMBL29925444 | 0.87 | MAPT (0.55) | LMNAMAPTTP53TSHRRAB9A | |
| SCHEMBL11013003 | 0.86 | MAPT (0.67) | LMNAMAPTTP53TSHRRAB9A | |
| Hydrochloric Acid SCHEMBL29924956 | 0.86 | MAPT (0.54) | LMNAMAPTTP53TSHRRAB9A | |
| SCHEMBL3875610 | 0.84 | LMNA (0.61) | LMNAMAPTTP53TSHRRAB9A | |
| Bromide SCHEMBL3865725 | 0.83 | LMNA (0.57) | LMNAMAPTTP53TSHRRAB9A | |
| SCHEMBL30537908 | 0.83 | LMNA (0.69) | LMNAMAPTTP53RAB9ASMN1; SMN2 | |
| SCHEMBL24741270 | 0.82 | LMNA (0.57) | LMNAMAPTTP53APPTHRB | |
| SCHEMBL29924863 | 0.82 | LMNA (0.57) | LMNAMAPTTP53APPTHRB | |
| SCHEMBL13291441 | 0.82 | MAPT (0.80) | LMNAMAPTTP53TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601846-B2 | Compounds having activity as inhibitors of apoptosis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-10-13 | — | — | US | disclosed |
| US-20060122178-A1 | Compounds having activity as inhibitors of apoptosis | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122178-A1 | Compounds having activity as inhibitors of apoptosis | BAD, CASP3, BAX | LMNA 1024/4885MAPT 3248/4885TP53 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.